162 related articles for article (PubMed ID: 23010502)
1. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study.
Charbonneau B; Maurer MJ; Ansell SM; Slager SL; Fredericksen ZS; Ziesmer SC; Macon WR; Habermann TM; Witzig TE; Link BK; Cerhan JR; Novak AJ
Cytokine; 2012 Dec; 60(3):882-9. PubMed ID: 23010502
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based case-control study.
Chang CM; Wang SS; Dave BJ; Jain S; Vasef MA; Weisenburger DD; Cozen W; Davis S; Severson RK; Lynch CF; Rothman N; Cerhan JR; Hartge P; Morton LM
Int J Cancer; 2011 Aug; 129(4):938-47. PubMed ID: 20949561
[TBL] [Abstract][Full Text] [Related]
3. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma.
Hu W; Bassig BA; Xu J; Zheng T; Zhang Y; Berndt SI; Holford TR; Hosgood HD; Leaderer B; Yeager M; Menashe I; Boyle P; Zou K; Zhu Y; Chanock S; Lan Q; Rothman N
Environ Mol Mutagen; 2013 Jan; 54(1):72-7. PubMed ID: 23055202
[TBL] [Abstract][Full Text] [Related]
6. Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case-control study.
Mildon KH; Ansell P; Roman E; Kane EV
Cancer Causes Control; 2010 Dec; 21(12):2079-83. PubMed ID: 20697798
[TBL] [Abstract][Full Text] [Related]
7. Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.
Rhee J; Birmann BM; De Roos AJ; Epstein MM; Martinez-Maza O; Breen EC; Magpantay LI; Levin LI; Visvanathan K; Hosgood HD; Rohan TE; Smoller SW; Bassig BA; Qi L; Shu XO; Koh WP; Zheng W; Yuan JM; Weinstein SJ; Albanes D; Lan Q; Rothman N; Purdue MP
Int J Cancer; 2023 Mar; 152(5):865-878. PubMed ID: 36151863
[TBL] [Abstract][Full Text] [Related]
8. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.
Charbonneau B; Maurer MJ; Fredericksen ZS; Zent CS; Link BK; Novak AJ; Ansell SM; Weiner GJ; Wang AH; Witzig TE; Dogan A; Slager SL; Habermann TM; Cerhan JR
Am J Hematol; 2012 Sep; 87(9):880-5. PubMed ID: 22718493
[TBL] [Abstract][Full Text] [Related]
9. Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study.
Kleinstern G; Camp NJ; Berndt SI; Birmann BM; Nieters A; Bracci PM; McKay JD; Ghesquières H; Lan Q; Hjalgrim H; Benavente Y; Monnereau A; Wang SS; Zhang Y; Purdue MP; Zeleniuch-Jacquotte A; Giles GG; Vermeulen R; Cocco P; Albanes D; Teras LR; Brooks-Wilson AR; Vajdic CM; Kane E; Caporaso NE; Smedby KE; Salles G; Vijai J; Chanock SJ; Skibola CF; Rothman N; Slager SL; Cerhan JR
Cancer Epidemiol Biomarkers Prev; 2020 May; 29(5):1074-1078. PubMed ID: 32108027
[TBL] [Abstract][Full Text] [Related]
10. Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development.
Saberi Hosnijeh F; Kolijn PM; Casabonne D; Nieters A; Solans M; Naudin S; Ferrari P; Mckay JD; Weiderpass E; Perduca V; Besson C; Mancini FR; Masala G; Krogh V; Ricceri F; Huerta JM; Petrova D; Sala N; Trichopoulou A; Karakatsani A; La Vecchia C; Kaaks R; Canzian F; Aune D; Boeing H; Schulze MB; Perez-Cornago A; Langerak AW; van der Velden VHJ; Vermeulen R
Sci Rep; 2020 Aug; 10(1):13814. PubMed ID: 32796953
[TBL] [Abstract][Full Text] [Related]
11. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
13. Serum level of soluble interleukin-2 receptor correlates with CD25 expression in patients with T lymphoblastic lymphoma.
Toji T; Takata K; Sato Y; Miyata-Takata T; Hayashi E; Habara T; Maeda Y; Tanimoto M; Yoshino T
J Clin Pathol; 2015 Aug; 68(8):622-7. PubMed ID: 25935549
[TBL] [Abstract][Full Text] [Related]
14. Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma.
Tada K; Kim SW; Asakura Y; Hiramoto N; Yakushijin K; Kurosawa S; Tajima K; Mori S; Heike Y; Tanosaki R; Maeshima AM; Taniguchi H; Furuta K; Kagami Y; Matsuno Y; Tobinai K; Takaue Y; Fukuda T
Am J Hematol; 2012 Aug; 87(8):770-5. PubMed ID: 22641292
[TBL] [Abstract][Full Text] [Related]
15. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.
Tefferi A; Vaidya R; Caramazza D; Finke C; Lasho T; Pardanani A
J Clin Oncol; 2011 Apr; 29(10):1356-63. PubMed ID: 21300928
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.
Gupta M; Stenson M; O'Byrne M; Maurer MJ; Habermann T; Cerhan JR; Weiner GW; Witzig TE
Ann Oncol; 2016 Jan; 27(1):165-72. PubMed ID: 26487586
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes.
Levin LI; Ramirez CM; Liao EL; Guo H; Kim BK; Marrogi AJ; Magpantay LI; Breen EC; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):233-241. PubMed ID: 36409490
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of Diffuse Large B-cell Lymphoma From Follicular Lymphoma Using Texture Analysis on Conventional MR Images at 3.0 Tesla.
Wu X; Sikiö M; Pertovaara H; Järvenpää R; Eskola H; Dastidar P; Kellokumpu-Lehtinen PL
Acad Radiol; 2016 Jun; 23(6):696-703. PubMed ID: 26976622
[TBL] [Abstract][Full Text] [Related]
19. Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses.
Maeshima AM; Omatsu M; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2008 Sep; 99(9):1760-8. PubMed ID: 18549405
[TBL] [Abstract][Full Text] [Related]
20. Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium.
Kane E; Skibola CF; Bracci PM; Cerhan JR; Costas L; Smedby KE; Holly EA; Maynadié M; Novak AJ; Lightfoot TJ; Ansell SM; Smith AG; Liebow M; Melbye M; Morton L; de Sanjosé S; Slager SL; Wang SS; Zhang Y; Zheng T; Roman E
Cancer Epidemiol Biomarkers Prev; 2015 Jul; 24(7):1061-70. PubMed ID: 25962811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
